In an interview with CURE®, Dr. Jorge Gomez discussed how recent developments in the assessment of biomarkers within the small cell lung cancer and non-small cell lung cancer space have led to approvals of new and expanded therapies.
Dr. Jorge Gomez
Advertisement
Articles by Dr. Jorge Gomez
An expert explains the importance of the fourth approval of the immunotherapy Tecentriq for certain patients with metastatic non-small cell lung cancer who have a high PD-L1 expression.
Advertisement
Latest Updated Articles
Tecentriq Approval in NSCLC 'Stops the Brakes' on PD-L1 ExpressionPublished: July 9th 2020 | Updated:
Success and Momentum Involving Biomarkers in Lung Cancer Has Led to More Treatment Options for PatientsPublished: July 24th 2020 | Updated:
Advertisement
Advertisement
